Truist raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $15 from $14 and keeps a Buy rating on the shares.The affordable medicines theme remains attractive heading into 2026, with Amneal offering a way to capture the opportunity, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces FDA approval for Boncresa, Oziltus BLAs
- Amneal Pharmaceuticals announces FDA approval for epinephrine injection vials
- Amneal Pharmaceuticals initiated with an Overweight at Barclays
- Amneal Pharmaceuticals announces results from Phase 4 ELEVATE-PD
- Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol